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In vivo activation of Wnt/β-catenin signaling to model Schwann cell tumors in mice 
 
Introduction 
While Wnt/β-catenin signaling has been demonstrated to be involved in a variety of cancers, such as lung, 
liver and brain tumors, it was only recently that our lab implicated this pathway in the development of Schwann cell 
tumors, including benign tumors known as neurofibromas, and malignant peripheral nerve sheath tumors 
(MPNSTs)—aggressive soft tissue sarcomas that originate in Schwan cells or Schwann cell precursors. (Watson et 
al., Cancer Discovery, 2013; Carrol and Ratner, Glia, 2008; MacDonald et al., Dev Cell, 2009). Approximately half 
of MPNSTs are developed by patients with Neurofibromatosis Type 1 Syndrome (NF1), a genetic disease 
characterized by a heterozygous loss of the Neurofibromin 1 gene (NF1), and half occur spontaneously (Evans et al, 
J Med Genet, 2002). In its normal role as a Ras GTPase-activating protein, NF1 functions as a tumor suppressor 
gene by negatively regulating Ras (Xu et al, Cell, 1990). It is known that in NF1 patients, loss of the second copy of 
the NF1 gene results in the development of neurofibromas, and 10% of these will incur further genetic changes that 
result in the transformation to MPNSTs (Evans et al, J Med Genet, 2002; Katz et al., Expert Rev Mol Med, 2009). 
Current treatments of MPNSTs are far from effective, with 5-year survival rates currently below 40%; therefore a 
better understanding of the genetic mechanisms by which these tumors form and progress is essential to developing 
better therapies (Kolberg, Neuro Oncol., 2013). 
Research in the Largaespada lab, utilizing a Sleeping Beauty forward genetic screen, identified multiple 
genes implicating canonical Wnt signaling in the development of MPNSTs (Rahrmann et al, Nature Genetics, 
2013). Several mouse models for MPNSTs also demonstrate activation of this pathway (Watson et al, Cancer 
Discovery, 2013). In addition, quantitative real-time PCR (QPCR), gene expression microarray, and tissue 
microarray analyses have confirmed activation of this pathway in many or most human neurofibromas and MPNST 
samples (Watson et al, Cancer Discovery, 2013). In vitro studies have shown that activation of Wnt signaling alone 
was able to produce oncogenic phenotypes in immortalized human Schwann cells, and down-regulation of the 
pathway in human MPNST cells was able to mitigate the oncogenic properties in these cells. In immortalized human 
Schwann cell lines, activating Wnt/β-catenin signaling by multiple mechanisms, including overexpression of 
activated β-catenin, and knockdown of β-catenin destruction member components, was sufficient to increase cellular 
proliferation and anchorage-independent growth (Watson et al, Cancer Discovery, 2013). Using shRNA constructs 
targeted for β-catenin, we observed diminished Wnt signaling, as well as reduced proliferation, anchorage-
independent growth, and xenograft tumor formation in both NF1-associated and sporadic MPNST cell lines 
(Watson et al, Cancer Discovery, 2013). While these studies point to the importance of Wnt/β-catenin signaling in 
vitro, they do not demonstrate what effect overexpression of β-catenin and activation of the Wnt pathway in 
Schwann cells has in the context of an in vivo mouse model. It was our hypothesis that by expressing an activated 
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form of β-catenin in the Schwann cells of mice, Wnt signaling would be activated, and nerve hyperplasia and 
Schwann cell tumors would develop.  In addition, as it has previously been shown in an in vivo mouse model that bi-
allelic loss of Nf1 in the Schwann cells of adult mice leads to the development of neurofibromas, we predicted that 
expression of activated β-catenin with this background would act cooperatively in the development of Schwann cell 
tumors, resulting in decreased tumor latency, increased tumor burden, and higher tumor grade (Mayes et al, Cancer 
Research, 2011; Wu et al, Cancer Cell, 2008). 
 
Methods 
In order to investigate the role of Wnt signaling in the development of MPNSTs in vivo, we utilized a 
mouse model expressing an activated form of β-catenin in Schwann cells. Mutations that stabilize β-catenin and 
prevent its degradation are found in a variety of human cancers, allowing activation of Wnt signaling (Harada et al, 
EMBO, 1999). Taking advantage of this, we implemented a Cre-Lox system in which Exon 3 of β-catenin, which 
contains a critical site of phosphorylation, is between loxP sequences (Ctnnb1lox(ex3)), and its removal results in a 
constitutively active form of β-catenin (Harada et al, EMBO, 1999). In a separate mouse strain, the desert hedgehog 
(Dhh) regulatory sequence was used to control expression of Cre Recombinase in Schwann cells and Schwann cell 
precursors, the cell of origin for neurofibromas and MPNSTs (Keng et al, Sarcoma, 2012; Carroll and Ratner, Glia, 
2008; ; Wu et al, Cancer Cell, 2008 ).When Ctnnb1lox(ex3) mice and Dhh-Cre are crossed, Dhh-Cre; Ctnnb1lox(ex3) 
mice will be produced that express the activated form of β-catenin in the Schwann cells and Schwann cell precursors. 
As activation of the Wnt pathway has been shown to induce an oncogenic phenotype in vitro, we hypothesized that 
activation of this pathway through the expression of an activated form of β-catenin would have the a similar effect in 
an in vivo mouse model, leading to nerve hyperplasia, and the formation of peripheral nervous system tumors that 
model Schwann cell tumors seen in human patients. In addition, to determine if activation of Wnt signaling 
cooperates with loss of Nf1 in mice for Schwann cell tumorigenesis, we concurrently crossed in an Nf1 floxed allele 
to our Dhh-Cre; Ctnnb1lox(ex3) mice (Wu et al, Cancer Cell, 2008) . This cross would result in mice of three possible 
genotypes: Dhh-Cre; Ctnnb1lox(ex3),  Dhh-Cre; Nf1flox/+; Ctnnb1lox(ex3), and Dhh-Cre; Nf1flox/flox; Ctnnb1lox(ex3). As it is 
known that loss of NF1 alone is insufficient for malignant tumor formation and other genetic changes are necessary 
for this to occur, characterization of these progeny would give us insight into the effect of Wnt activation on 
MPNST development in NF1 patients (Bajenaru et al, Mol Cell Biol, 2002; Wu et al, Cancer Cell, 2008 ).  
DNA was isolated from tail clippings using proteinase K treatment, phenyl chloroform extraction, and 
ethanol precipitation, and was dissolved in sterile TE [10 mmol/L tris-HCl (pH7.5), 1 mmol/L EDTA (pH 8)]. 
For PCR genotyping, three primers were used to distinguish between wild-type (WT) Ctnnb1 and Ctnnb1lox(ex3: 5’ 
GGACAATGGCTACTCAAGGTTTGTG 3’, 5’ CTAAGCTTGGCTGGACGTAAACTC 3’, and 5’ACGTGT 
GGCAAGTTCCGCGTCATCC 3’ (Jackson Laboratories). Primers for the Nf1 floxed allele were WT forward 5’ 
CTTCAGACTGATT GTTGTAACTGA 3’, WT reverse 5’ ACCTCTCTAGCCTCAGGAATGA 3’, and floxed 
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reverse 5’ TGATTCCC ACTTTGTGGTTCTAAG; and for Dhh-Cre were forward 5’ 
CTGGCCTGGTCTGGACACAGTGCC 3’ , and reverse 5’ CAGGGTCCGCTCGGGCATAC 3’ (Keng et al, 
Cancer Res., 2012). PCR products were separated on 2% agarose gel and presence or absence of amplicons used to 
determine genotype. Mice of desired genotypes were weaned, and subsequently monitored daily for signs of overall 
health, including weight, mobility, and coordination. When moribund, necropsies were performed in which any 
tumors were characterized by number, size, and grade; and nerves were observed for hyperplasia and tumor formation. 
All abnormal nerves were assessed for tumor grade using well established immunohistochemistry and staining 
methods. Specifically, sections of formalin fixed tissue were stained with hemotoxin and eosin, S100 (a Schwann cell 
marker), and Ki67 (proliferation marker), and were examined histopathologically for signs of hyperplasia and/or 
tumor grade (Keng et al, Sarcoma, 2012).  
Results 
During the extensive breeding process, it became apparent that we were getting far fewer Dhh-Cre; 
Ctnnb1lox(ex3) pups than would be expected by Mendelian inheritance of the alleles. It appears as though activation of 
Wnt signaling in Dhh positive cells is semi-lethal, as just four Dhh-Cre; Ctnnb1lox(ex3) mice were generated, each of 
which died before necropsies could be performed, living an average 33 days (Figure 1).  Ten Dhh-Cre; Nf1flox/+; 
Ctnnb1lox(ex3) mice were generated, living an average of approximately 44 days (Figure 1). Five of these mice died 
before necropsies were performed, and necropsies of these remaining mice revealed no tumors or enlarged nerves 
(Figure 2). Also of interest, each of these five mice was revealed to have an enlarged heart, and several displayed 
discoloration of the lungs and/or intestines. The four Dhh-Cre; Nf1flox/flox; Ctnnb1lox(ex3) mice generated lived an 
average of ~48 days, two of which died prior to necropsy, and examination of the remaining two mice revealed no 
tumors and no enlarged nerves (Figure 1, 2). While tumor formation or significant nerve hyperplasia was not 
observed in any of the mice generated, this may be at least partially attributed to the drastically reduced life span that 
was characteristic of this mouse model. In comparison to Dhh-Cre; Nf1flox/+ and Dhh-Cre; Nf1flox/flox mice, mice 
expressing activated β-catenin—regardless if Nf1 alleles were wild-type or floxed—had substantially diminished life-
spans, the longest of which was just 77 days. Analysis using two-tailed t-tests revealed difference in length of life 
between Dhh-Cre; Nf1flox/+ or Dhh-Cre; Nf1flox/flox and each cohort expressing activated β-catenin to be very 
significant (p-value <<0.0001) (Figure 1). However, differences in length of life were not statistically significant 
between the three cohorts expressing activated β-catenin, demonstrating that activated β-catenin expression is largely 
responsible for the diminished viability of these mice (Figure 1). 
 
Discussion and Future Direction 
In addition to conclusions regarding abnormal Wnt/β-catenin signaling, we also see the importance of 
Wnt/β-catenin signaling in normal development. Normally, this signaling pathway is strictly regulated, and in the 
absence of Wnt signaling, β-catenin is phosphorylated and tagged for destruction by the β-catenin destruction 
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complex. However, the activated form of β-catenin utilized in this mouse model cannot be phosphorylated, and even 
in the absence of extracellular Wnt signaling can accumulate in the cytoplasm, enter the nucleus, complex with 
members of the Tcf/Lef  family, and act as a transcriptional activator of Wnt target genes, including cell 
proliferation activators such as c-Myc and cyclin D1 (Barker, Methods Mol Biol, 2008).  It is clear for this mouse 
model that when Schwann cells constitutively receive proliferative signals in the absence of stimulatory signaling, the 
abnormal signaling and proliferation that results has disastrous consequences for development; evidenced in the small 
cohorts generated, diminished length of life, and phenotypic abnormalities, including discoloration of organs, and 
enlargement of the heart. Given the pervasiveness of this last phenotype, it is likely that expression of activated β-
catenin in Schwann cells results in abnormal heart development, contributing greatly to the diminished viability of 
this model. Schwann cells are known to serve an important role in angiogenesis and neural remodeling in cardiac 
ganglia through their secretion of cytokines such as vascular endothelial growth factor (VEGF), and it is likely that 
the expression of activated β-catenin alters this signaling in a manner which often proves lethal (Wang et al, Mol 
Cell Biochem, 2012). VEGF is a pleiotropic factor in the developing embryonic heart, regulating vasculogenesis and 
angiogenesis, as well as survival in endothelial cells (Armstrong and Bischoff, Heart Valve Development, 2004). As 
activated β-catenin expression has been shown to up-regulate VEGF-A mRNA and protein levels by three fold in 
normal colon epithelial cells, it is plausible that this mechanism is also acting in Schwann cells, resulting in the 
characteristic enlarge heart phenotype we observed, as well as the semi-lethal consequence of activated β-catenin 
expression (Easwaran et al, Cancer Res, 2003). 
 Apart from demonstrating important consequence of activated β-catenin expression in the Schwann cells of 
developing mice, these experiments provide a foundation on which to pursue the full characterization of a related 
model—one which implements an inducible Cre-Lox recombination system. A fusion between Cre recombinase and 
a mutated ligand-binding domain of the human estrogen receptor (ER) yields a tamoxifen dependent Cre 
recombinase, Cre-ERT (Feil et al, Handb Exp Pharmacol, 2007). In the absence of tamoxifen,  Cre-ERT is bound to 
heat shock protein-90 in the cytoplasm and is therefore inactive; however, upon treatment with tamoxifen, Cre-ERT 
binds tamoxifen, translocates to the nucleus, and engages target DNA to induce recombination (Liu et al, PLos One. 
2010). In order to cause recombination specifically in Schwann cells, regulatory sequences of myelin proteolipid 
protein (Plp)—a component of Schwann cell myelin sheath—has been used to control Cre-ERT transcription 
(Mallon et al, Neurosci, 2002; Doerflinger et al, genesis, 2002). Cre-ERT  under this transcriptional control—
designated Plp-Cre—has been successfully implemented to induce Nf1 loss of function in an in vivo mouse model, 
and demonstrated that Nf1 inactivation in Schwann cells after birth or in adult animals results in enlarged peripheral 
nerves, and formation of neurofibromas (Mayes et al, Cancer Research, 2011). We will utilize this Plp-Cre 
recombination system  to induce the expression of activated β-catenin and the inactivation of Nf1 expression in 
adult mice, allowing the developmental consequences encountered with the Dhh-Cre system to be avoided. The 
experimental plan is as follows: 
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1. Plp-Cre mice will be crossed with Nf1flox/flox; Ctnnb1lox(ex3) mice and the resulting offspring will be intercrossed to 
obtain 30 mice per cohort of Plp-Cre; Ctnnb1lox(ex3)/+,  Plp-Cre; Nf1flox/+; Ctnnb1lox(ex3)/+,  and PLP-Cre; 
Nf1flox,flox; Ctnnb1lox(ex3)/+. In addition 15 PLP-Cre; Nf1lox/flox  will be generated. Crosses are currently in progress 
for this model, and we will shortly begin tamoxifen injections (Table 1). 
2. Mice will be aged to 60 days at which point they will be injected twice a day for three consecutive days with 
1mg tamoxifen dissolved in 100 µL 9:1 sunflower seed oil/ethanol to induce recombination (Mayes et al, 
Cancer Research, 2011). Mice will be monitored daily for signs of overall health, including weight, mobility, 
and coordination. 
3. When mice become moribund, necropsies will be performed in which tumors will be characterized by number, 
size, and grade; and nerves will be observed for hyperplasia and tumor formation. All abnormal nerves will be 
assessed for tumor grade using well established immunohistochemistry and staining methods. Specifically, 
sections of formalin fixed tissue will be stained with hemotoxin and eosin, S100 (a Schwann cell marker), and 
Ki67 (proliferation marker), and will be examined histopathologically for signs of hyperplasia and/or tumor 
grade (Keng et al, Sarcoma, 2012). 
4. Two methods will be used to validate that Wnt signaling has been activated. Western blot analysis will be used 
to confirm expression of activated β-catenin, and QPCR will be used to quantify expression of genes activated 
by Wnt signaling, including C-Myc (MYC), lymphoid enhancer-binding factor 1 (LEF1), axis inhibitor 2 
(AXIN2), CyclinD1 (CCND1), and Survivin (BIRC5). Expression levels will be compared between wild type 
mice, Plp-Cre; Nf1flox/flox  mice, and the three experimental groups expressing activated  β-catenin, as well as in 
Schwann cells versus other cell types to verify that Wnt signaling is only activated in Plp-Cre expressing cells. 
 
Utilization of this strategy will allow us to avoid the disastrous effects activated β-catenin expression poses to normal 
development, and give us insight into the role of this signaling pathway in Schwann cell tumorigenesis, for both 
spontaneous cases and those in the context of NF1 patients.  
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Tables and Figures 
 
Figure 1 
Average length of life for A) Dhh-Cre; Ctnnb1lox(ex3),  Dhh-Cre; Nf1flox/+; Ctnnb1lox(ex3), and Dhh-Cre; Nf1flox/flox; Ctnnb1lox(ex3) mice 
were not significantly different from one another (p-values>0.05) according to two-tailed t-test. SEM error bars included. B) 
Dhh-Cre; Ctnnb1lox(ex3),  Dhh-Cre; Nf1flox/+; Ctnnb1lox(ex3), and Dhh-Cre; Nf1flox/flox; Ctnnb1lox(ex3) mice lived significantly shorter 
than Dhh-Cre; Nf1flox/+ and Dhh-Cre; Nf1flox/flox (p-values<<0.0001) according to two-tailed t-test. SEM error bars included. C) 
Kaplan Meier graph showing percent survival as a function of time (days) of experimental cohorts in reference to Dhh-Cre; 
Nf1flox/+ and Dhh-Cre; Nf1flox/flox mice. Mice were monitored daily for signs of overall health and euthanized when paralyzed, 
failed to groom, or lost significant weight. Graph is representative of four Dhh-Cre; Ctnnb1lox(ex3) mice, all of which died before 
necropsy; ten Dhh-Cre; Nf1flox/+; Ctnnb1lox(ex3) mice, five of which died before necropsy; and Dhh-Cre; Nf1flox/flox; Ctnnb1lox(ex3), 
two of which died before necropsy. Ctnnb1lox(ex3) indicates that exon 3 is  flanked by LoxP sequences in one or both alleles of β-
catenin. 
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Figure II 
Mice were sacrificed using CO2-euthanasia immediately prior to necropsy. Mice expressing activated β-catenin in Schwann cells 
showed no significant nerve hyperplasia, as indicated by trigeminal nerves (on bottom of brain), dorsal root ganglia, and sciatic 
nerves of comparable size and morphology to those of wild-type mice. However, Dhh-Cre; Nf1flox/+; Ctnnb1lox(ex3) and Dhh-Cre; 
Nf1flox/flox; Ctnnb1lox(ex3) mice often displayed an enlarged heart and discolored intestines and/or lungs. 
 
Table 1 
Cohorts of mice generated as of 2/24/14 for tamoxifen inducible PLP-Cre mouse model. Breeder mice  
without PLP-Cre allele are not included in this census. 5’ GCGGTCTGGCAGTAAAAACTATC 3’ 
and 5’ GTGAAACAGCATTGCTGTCACTT 3’ used for PCR genotyping of PLP-Cre allele. 
 PLP-Cre; Ctnnb1lox(ex3)/+ PLP-Cre; 
Nf1flox/+ 
PLP-Cre; 
Nf1flox/+; 
Ctnnb1lox(ex3)/+ 
PLP-Cre; 
Nf1flox/flox; 
Ctnnb1lox(ex3)/+ 
A
ge
 (d
ay
s)
 a
s o
f 2
/2
4/
14
 
85 61 61 32 
85 61 61  
64 61 55  
55 61 55  
39  49  
  49  
  49  
  49  
  39  
  32  
  32  
Total 5 4 11 1 
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